Drug intelligence / Profile preview

interferon alfa-2a

Development stage: Phase 4
Lead developer: Roche
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intramuscular, Intralesional

Overview

Interferon alfa‑2a is a recombinant form of human interferon alpha, a type I interferon consisting of 165 amino acids. It is produced using recombinant DNA technology and closely resembles the naturally occurring leukocyte-derived interferons. Interferon alfa‑2a acts as an immunomodulator and antiviral agent by stimulating the innate immune response, inhibiting viral replication, and modulating cell growth. It is approved for use in treating chronic hepatitis B and C infections, Philadelphia chromosome-positive chronic myelogenous leukemia (CML), hairy cell leukemia, AIDS-related Kaposi's sarcoma, malignant melanoma, condylomata acuminata (genital warts), lymphoma, and renal cell carcinoma[1][3][5][7]. Its mechanism involves binding to specific cell surface receptors to activate intracellular signaling pathways that enhance immune responses against viruses and tumor cells.

Brand names: Roferon-A
Other names: Interferon alfa-2a (recombinant)Recombinant human interferon alfa-2arIFN-alpha-2arIFN-alpha2arIFN-alpha 2aSH-polypeptide-46SH-polypeptide46SH-polypeptide 46Interferon-alfa 2aInterferon-alfa2aInterferon-alfa-2a

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on interferon alfa-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alfa-2a.

Explore the full profile